(Shanghai, November 7, 2022) The "Lung 'Assisted' Good Words" lung cancer popular science video challenge event initiated by the People's Daily Health Client and supported by two leading companies in the pharmaceutical and medical technology industry, Roche Pharmaceutical China and Medtronic, jointly supported by public welfare, was successfully concluded during the 5th China International Import Expo .
This activity aims to enhance the public's correct understanding of lung cancer and enhance the understanding of standardized treatment of lung cancer, especially non-small cell lung cancer, . The event invited multiple authoritative teams of experts in China to jointly produce creative videos, combine minimally invasive surgical techniques for lung cancer to display and explain lung cancer diagnosis and treatment knowledge, and conduct popular science education on lung cancer diseases and standardized diagnosis and treatment to the public.
novel breaks the circle, upgrades gameplay, challenge and innovates the height of
is different from most lung cancer popular science popularization, the doctors participating in the video challenge not only "touch" but also "take hands" to intuitively demonstrate the skills in lung cancer surgery, such as surgical robot challenge peeling tomato skin, suture needle picking sugar challenge, underwater peeling grape skin , surgical equipment lego, grapefruit stripping surgery challenge, etc. combines daily life with games, integrates professionalism into life, turns boring into fun, and shows multi-dimensional means such as early lung cancer surgical treatment, postoperative auxiliary immunotherapy and other multi-dimensional means to improve the understanding of standardized diagnosis and treatment of lung cancer , especially the important role of postoperative auxiliary immunotherapy in reducing the risk of recurrence in early lung cancer patients. Up to now, the total number of views of related challenge videos has exceeded one million, which has attracted great attention from the society.
During the 5th China International Import Expo, the People's Daily Health Client, the initiator of the event, issued honorary certificates to experts such as First Affiliated Hospital of Zhejiang University Professor Hu Jian, Peking University People's Hospital Professor Yang Fan, First Affiliated Hospital of Zhengzhou University Professor Zhao Song, Professor Ge Di, Zhongshan Hospital of Fudan University, and Professor Chen Chun, Joint Hospital of Fujian Medical University, and other experts, thanking them for their authoritative opinions to the event.
"Lung Assistance Good Words" Expert Certification Ceremony
First Affiliated Hospital of Zhejiang University School of Medicine Professor Hu Jian introduced: "With the help of the People's Daily Health Client, a high-influence media platform, We hope to combine interesting video challenges with popular science of lung cancer disease, and to present innovative solutions for lung cancer diagnosis and treatment to the majority of patients and the public. We hope that through this circle-breaking activity, will have more public attention to lung cancer, and we also hope that patients can gain more understanding of all-round and multi-dimensional individualized and precise treatment."
Healthy China, popular science first, and improve the scientific innovation capabilities of
Experts said that suffering from lung cancer does not mean that they have obtained a "death notice". Professor Yang Fan of Peking University People's Hospital said: "In the past 10 years, with the advancement of diagnosis and treatment methods, the survival rate of lung cancer in my country has generally shown an upward trend. With the application and promotion of various innovative treatment methods in clinical practice, lung cancer has entered the era of 'precise treatment', and the survival rate of patients has been significantly improved. Patients with different types of lung cancer can find treatment options that suit them. Lung cancer treatment is gradually moving towards chronic disease management. "
In recent years, the Party and the country have attached great importance to the cause of cancer prevention and control, and have clearly listed it as one of the major actions in the "Healthy China Action (2019-2030)". Just this year, the General Office of the CPC Central Committee and the General Office of the State Council issued the " Opinions on Further Strengthening the Popularization of Science and Technology in the New Era" and clearly stated that insisted on putting science popularization at the same level as scientific and technological innovation , strengthened the science popularization responsibility of the whole society, and improved the science popularization capabilities and the scientific literacy of the whole people. As one of the most common malignant tumors in my country, the incidence and mortality of lung cancer rank first among malignant tumors 1, and is the "first cancer killer" in my country and seriously threatens the health of the public. While innovative treatment plans for lung cancer continue to emerge, it is also particularly important to enhance the public's awareness of standardizing lung cancer diagnosis and treatment.
Professor Zhao Song, the First Affiliated Hospital of Zhengzhou University, said, "With the improvement of my country's cancer prevention and treatment level, lung cancer patients can effectively improve the survival rate of 5 years by receiving standardized diagnosis and treatment - the premise is how breaks the public's inherent impression of irreversible cancer, so that everyone no longer "fears talking about cancer", and improves the public's correct understanding of lung cancer . I am very happy to participate in the "auxiliary" lung cancer popularization video challenge activity. This is a creative and fresh experience, and will bring difficult lung cancer treatment plans, such as surgical treatment and postoperative surgery. Professional terms such as adjuvant therapy are presented to the audience in an intuitive and popular way, and show the cutting-edge treatment plan for lung cancer in an innovative popular science form . "
focuses on lung cancer, standardizes treatment, and adds a BUFF
According to the latest "2020 Global Latest Cancer Burden Data" released by the World Health Organization International Cancer Research Institute, the global death toll in 2020 was about 1.8 million, far exceeding other cancer types. Lung cancer can be roughly divided into two categories: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Professor Ge Di of Zhongshan Hospital Affiliated to Fudan University introduced: "NSCLC is the most common type, accounting for about 85% of all cases 2. Early NSCLC patients can surgically remove the lesions 3, but more than 50% of patients who only undergo surgery will relapse or metastasis within 5 years. eventually leads to treatment failure. This has become a major challenge in the clinical perioperative management of lung cancer. "
Professor Chen Chun of Union Hospital Affiliated to Fujian Medical University said: "For patients with non-small cell lung cancer, after surgical resection, they also need to receive adjuvant drug treatment, such as adjuvant chemoradiation and chemotherapy, adjuvant targeted therapy, adjuvant immunotherapy, etc. With adjuvant immunotherapy, Related to the breakthrough of research, assisted immunotherapy is expected to further improve patient prognosis, help patients consolidate treatment effects, and reduce the risk of disease recurrence . "
Roche demonstrated the independently developed PD-L1 inhibitor - Taishengqi ® (atilizumab), as the first 5 is also the only treatment plan approved in China for the indication for postoperative adjuvant immunotherapy for early NSCLC. Through postoperative adjuvant immunotherapy, Taishengqi ® can be used in NSCLC patients with stage II-IIIA PD-L1=1, reducing the risk of disease recurrence and death by 34%, and 60% of patients have no recurrence within three years. 6
Mr. Qian Wei, general manager of Roche Pharmaceuticals China tumor business, delivered a speech
Mr. Qian Wei, general manager of Roche Pharmaceuticals China tumor business, said: "Roche has been committed to promoting innovation in lung cancer diagnosis and treatment, and has also been actively participating in and supporting innovative science popularization activities. We are very happy to join hands with partners and experts to launch this creative science popularization video challenge. And share the results of the activity with all walks of life in 'Lung Cancer Focus Month'.
hopes that through this activity, we can enhance the public's awareness of lung cancer, popularize the awareness of standardized diagnosis and treatment of lung cancer, and encourage patients to fight the disease with a positive attitude. In the future, Roche will continue to adhere to the concept of "going first with the needs of patients". While continuing to bring innovative treatment plans, we will gather forces from all parties to build a communication bridge between patients, doctors, and industry partners, and jointly practice the great vision of " Healthy China 2030".”
references
[1]Zhang Xuchao, Liu Xiaoqing, Wang Jie, et al. Guidelines for diagnosis and treatment of non-small cell lung cancer with positive and ROS1-positive non-small cell lung cancer in Chinese anaplastic lymphoma [J]. Chinese Journal of Pathology, 2018, 47(4):7.
[2]Jeroen, N. Hiltermann, Anthonie, et al. Promote the development of circulating tumor cells and lung cancer [J]. International Journal of Pathology and Clinical Medicine, 2013, 33(5):374-375.
[3]The consensus group on the adjuvant treatment of thoracic surgery in non-small cell lung cancer. The consensus on the adjuvant treatment of postoperative non-small cell lung cancer in Chinese thoracic surgery (2018 edition). Chinese Journal of Lung Cancer, 2018, 21(10):731-737.
[4] Chinese Society of Clinical Oncology (CSCO, Chinese Society of Clinical Oncology), Lung Cancer Professional Committee of the Chinese Anti-Cancer Association. Expert consensus on perioperative treatment of early lung cancer. Evidence-based Medicine, 2019, 19(4):193-199.
[5] As of March 16, 2022, the day of approval was approved.
[6]Heather A. Wakelee, et al. IMpower 010: Primary results of a phase III global study of atezolizumab versus best support care after adjuvant chemotherapy in respected stage IB-IIIA non-small cell lung cancer (NSCLC). 2021 ASCO. Abstract 8500
written | Jianshijun
Edited by Jiang Yun Jiating
operation | 23
#Roche Pharmaceutical##Innovative Pharmaceutical Enterprise#
